WO2008052167A2 - Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication - Google Patents

Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication Download PDF

Info

Publication number
WO2008052167A2
WO2008052167A2 PCT/US2007/082683 US2007082683W WO2008052167A2 WO 2008052167 A2 WO2008052167 A2 WO 2008052167A2 US 2007082683 W US2007082683 W US 2007082683W WO 2008052167 A2 WO2008052167 A2 WO 2008052167A2
Authority
WO
WIPO (PCT)
Prior art keywords
intron
polymorphism
seq
patients
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/082683
Other languages
English (en)
French (fr)
Other versions
WO2008052167A3 (en
Inventor
Francis J. Mcmahon
Gonzalo E. Laje
Silvia Paddock
Husseini K. Manji
A. John Rush
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
US Department of Health and Human Services
Original Assignee
University of Texas System
University of Texas at Austin
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, US Department of Health and Human Services filed Critical University of Texas System
Priority to JP2009534893A priority Critical patent/JP2010508029A/ja
Priority to CA 2667812 priority patent/CA2667812A1/en
Priority to EP07868595A priority patent/EP2087136A2/en
Publication of WO2008052167A2 publication Critical patent/WO2008052167A2/en
Publication of WO2008052167A3 publication Critical patent/WO2008052167A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • Depression is a disease that affects a large proportion of the population and is a result of multiple factors. According to the World Health Organization (WHO), depression ranks among the ten leading causes of disability and will become the second-largest cause of the global health burden by 2020. An estimated 121 million people worldwide suffer from a depressive disorder for which they require treatment. It is estimated that 5.8% of all men and 9.5% of all women will suffer from a depressive disorder in any given year and that 17% of all men and women will suffer from a depressive disorder at some point in their lives.
  • WHO World Health Organization
  • SSRIs selective serotonin reuptake inhibitors
  • MAOIs monoamine oxidase inhibitors
  • the invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
  • GRIA3 glutamate receptor ionotropic AMPA 3
  • STAR* D Sequenced Treatment Alternatives to Relieve Depression
  • SSRI selective serotonin reuptake inhibitor
  • the inventors identified genetic markers that identify patients at high risk of developing suicidal thoughts during treatment with the SSRI citalopram.
  • the markers reside in the genes glutamine receptor, ionotropic, kainate 2 (GRIK2) and glutamate receptor ionotropic AMPA 3 (GRIA3).
  • Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists.
  • GRIK2 encodes a subunit of a kainate glutamate receptor. GRIK2 also is known as EAA4, GLR6, GLUR6, GLuR-6, and GluR-6. GRIK2 is located on chromosome 6ql6.3- q21. GRIK2 is identified by GenBank Accession Numbers BC037954 and AAH37954, as well as IMAGE clone 5728492.
  • GRIA3 belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternative splicing results in several different isoforms which may vary in their signal transduction properties. GRIA3 also is known as GLUR-K3, GLUR3, GLURC, GluR-3, GluR-K3, and gluR-C. GRIA3 is located on chromosome Xq25- q26. GRIA3 is identified by GenBank Accession Numbers BC032004 and AAH32004, as well as IMAGE clone 4753474.
  • the invention is directed to a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients that is associated with an increased risk of TESI, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of GRTK2, GRIA3, and combinations thereof.
  • TESI refers to the appearance of suicidal thoughts and/or behavior following treatment, such as treatment with SSRIs.
  • suicidal thoughts and behavior include, but are not limited to, the following: feeling that life is empty and/or wondering if life is worth living; thinking of suicide or death several times a week for several minutes; thinking of suicide or death several times a day in some detail; making specific plans for suicide; and attempting or succeeding in taking one's life.
  • a patient refers to an individual awaiting or under medical care and treatment, such as treatment for depression. While the inventive methods are designed for human patients (e.g., male and female human patients), such methods are applicable to any suitable individual, which includes, but is not limited to, a mammal, such as a mouse, rat, rabbit, hamster, guinea pig, cat, dog, goat, cow, horse, pig, and simian.
  • a mammal such as a mouse, rat, rabbit, hamster, guinea pig, cat, dog, goat, cow, horse, pig, and simian.
  • the sample of genetic material can be obtained from the patient by any suitable manner.
  • the sample can be isolated from a source including saliva, buccal cells, hair roots, blood, cord blood, amniotic fluid, interstitial fluid, peritoneal fluid, chorionic villus, semen, or other suitable cell or tissue sample. Methods for isolating genomic DNA from various sources is well-known in the art.
  • a polymorphism refers to one of multiple alleles of a gene.
  • the polymorphism is a single nucleotide polymorphism (SNP).
  • the polymorphism that is associated with an increased risk of TESI can be detected by any suitable manner known in the art.
  • the polymorphism can be detected by techniques, such as allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof.
  • intron 1 of GRIK2 typically comprises SEQ ID NO: 1, which contains a cytosine at position 201, rather than adenine (which is present in the GRIK2 intron 1 that is not associated with an increased risk of TESI).
  • intron 3 of GRIA3 typically comprises SEQ ID NO: 2, SEQ ID NO: 3, or .
  • SEQ ID NO: 2 contains a thymine at position 201, rather than adenine (which is present in the GRIA3 intron 3 that is not associated with an increased risk of TESI).
  • SEQ ID NO: 3 contains a guanine at position 201, rather than adenine (which is present in the GRIA3 gene that is not associated with an increased risk of TESI).
  • the invention also comprises assaying for the presence of a genotype that is associated with an increased risk of TESI, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of: glutamate receptor, ionotropic, N-methyl D-aspartate (GRIN) 2A; neurotrophic tyrosine receptor kinase (NTRK) 2; 5-hydroxytryptamine (serotonin) receptor (HTR) 3B; GRIAl; papilin (PAPLN); interleukin 28 receptor alpha (IL28RA); and combinations thereof.
  • GRIN glutamate receptor, ionotropic, N-methyl D-aspartate
  • NTRK neurotrophic tyrosine receptor kinase
  • HTR 5-hydroxytryptamine receptor
  • PAPLN interleukin 28 receptor alpha
  • IL28RA interleukin 28 receptor alpha
  • intron 3 of GRTN2A typically comprises SEQ ID NO: 4, which contains a cytosine at position 201, rather than adenine (which is present in the GRIN2A gene that is not associated with an increased risk of TESI).
  • intron 14 of NTRK2 typically comprises SEQ ID NO: 5, which contains a guanine at position 201, rather than adenine (which is present in the NTRK2 gene that is not associated with an increased risk of TESI).
  • intron 6 (GenBank Accession Number NM_006028).
  • intron 6 (boundary) of HTR3B typically comprises SEQ ID NO: 6, which contains a guanine at position 201, rather than adenine (which is present in the HTR3B gene that is not associated with an increased risk of TESI).
  • intron 5 of GRIAl typically comprises SEQ ID NO: 7, which contains a cytosine at position 201, rather than adenine (which is present in the GRIAl gene that is not associated with an increased risk of TESI).
  • intron 13 of PAPLN typically comprises SEQ ID NO: 8, which contains a guanine at position 201, rather than adenine (which is present in the PAPLN gene that is not associated with an increased risk of TESI).
  • nitron 13 (boundary) of PAPLN can comprise SEQ ID NO: 9, which contains a thymine at position 201, rather than a cytosine (which is present in the PAPLN gene that is not associated with an increased risk of TESI).
  • exon 7 of IL28RA typically comprises SEQ ID NO: 10, which contains a guanine at position 201, rather than adenine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
  • exon 7 of IL28RA can comprise SEQ ID NO: 11, which contains a thymine at position 201, rather than cytosine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
  • intron 4 of IL28RA typically comprises SEQ ID NO: 12, which contains thymine at position 201, rather than cytosine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
  • Sensitivity is the probability that a symptom is present (or the screening test is positive) when a patient has a disorder.
  • the sensitivity of the polymorphism associated with TESI in the inventive method can be any suitable sensitivity.
  • the sensitivity is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
  • Specificity is the probability that a symptom is not present (or the screening test is negative) when a patient does not have a disorder.
  • the specificity of the polymorphism associated with TESI in the inventive method can be any suitable specificity.
  • the specificity is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
  • Positive predictive value is the probability that a patient has a disorder given a positive test result.
  • the positive predictive value of the polymorphism associated with TESI in the inventive method can be any suitable value.
  • the positive predictive value is about 0.05 or higher (e.g., about 0.1, about 0.2, about 0.25, about 0.3, about 0.4, about 0.5, about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
  • Negative predictive value is the probability that a patient has the disorder given a negative test result.
  • the negative predictive value of the polymorphism associated with TESI in the inventive method can be any suitable value.
  • the negative predictive value is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
  • the invention also contains a kit comprising reagents suitable for applying the methods of the invention.
  • the kit provides the necessary materials for identifying the polymorphism packaged into a suitable container.
  • the kit contains a reagent that identifies a polymorphism in the selected gene that is associated with a selected trait, such as TESI.
  • the reagent is a set of primers or a PCR set (a set of primers, DNA polymerase, and 4 nucleoside triphosphates) that hybridizes with the gene or a fragment thereof.
  • the kit also can include other reagents for detecting or measuring the detectable entity and/or a control. Other reagents used for hybridization, prehybridization, DNA extraction, visualization, and the like also can be included.
  • This example demonstrates that genetic markers can be used to identify individuals with a major depressive disorder who develop treatment-emergent suicidal ideation (TESI) when exposed to a selective-serotonin reuptake inhibitor (SSRI), such as citalopram.
  • TESI treatment-emergent suicidal ideation
  • SSRI selective-serotonin reuptake inhibitor
  • DSM Diagnostic and Statistical Manual of Mental Disorders
  • AU participants received initial therapy with citalopram typically starting at 20 mg/day, with dose increases following recommended procedures (see Trivedi et al., Am. J. Psychiatry, 163(1): 28-40 (2006)).
  • SNPs single nucleotide polymorphisms
  • Genes were selected to sample five broad signaling pathways of potential importance in antidepressant effects: serotonin (20 genes), glutamate (16 genes), dopamine (3 genes), norepinephrine (4 genes), and neurotrophins (4 genes), as well as selected genes in other pathways (21 genes). All probands with TESI and a subset of probands without TESI were also screened with the Illumina 109K Exon-Centric chip, which measures the genotype of a DNA sample at each of 109,000 SNPs in and near most known human genes.
  • Allele and genotype frequencies were compared between the 120 participants who developed TESI and those who did not develop TESI. Allele-wise tests are most powerful for alleles that confer risk in a co-dominant or dominant fashion, while genotype- wise tests are more powerful when a recessive model applies. Allele-wise comparisons were performed with Cocaphase in the UNPHASED package (see Dudbridge et al., Am. J. Hum. Genet, 75(3): 424-435 (2004)), which estimates a likelihood-based test of association under the null hypothesis of all odds ratios (ORs) being equal to one. Genotype-wise comparisons were carried out using a Pearson Chi-square test on a 2 x 3 contingency table.
  • Table 1 includes demographic and clinical data for the 120 participants and the 1742 controls.
  • a Not significant b Defined as score of 5 or less on the last recorded visit.
  • the c index for this model is 0.73.
  • markers 157 and 239 are reported in Table 4.
  • the high-risk genotype of marker 157 correlates with a SNP in intron 1 of GRIK2 (e.g., SEQ ID NO: 1).
  • the high-risk alleles of marker 239 contain a SNP in intron 3 of GRIA3 (e.g., SEQ ID NOs: 2 and 3).
  • markers can help identify patients at high risk for TESI. Such patients will benefit from closer monitoring, alternative treatments, and/or specialty care. Such testing can allay the concern that has led regulatory agencies to issue warnings that contribute to a decrease in antidepressant prescriptions for patients who could benefit from them. Rather than broad warnings that can inappropriately affect antidepressant prescribing practices, identification of these markers indicates that narrower warnings could be appropriate that better capture the heterogeneous nature of TESI risk in those patients treated with antidepressants.
  • TESI TESI. These markers were identified in the following genes: GRIN2A, NTRK2, HTR3B,
  • GRIAl GRIAl
  • PAPLN PAPLN
  • NTRK2 e.g., SEQ ID NO: 5
  • intron 16 of HTR3B e.g., SEQ ID NO: 6
  • SEQ ID NO: 7 SEQ ID NO: 7
  • intron 13 of PAPLN e.g., SEQ ID NOs: 8 or 9

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/US2007/082683 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication Ceased WO2008052167A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009534893A JP2010508029A (ja) 2006-10-27 2007-10-26 抗うつ薬による治療時に有害事象を発現する危険性のある患者の識別方法
CA 2667812 CA2667812A1 (en) 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
EP07868595A EP2087136A2 (en) 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85497806P 2006-10-27 2006-10-27
US60/854,978 2006-10-27

Publications (2)

Publication Number Publication Date
WO2008052167A2 true WO2008052167A2 (en) 2008-05-02
WO2008052167A3 WO2008052167A3 (en) 2008-11-13

Family

ID=39276298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082683 Ceased WO2008052167A2 (en) 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication

Country Status (5)

Country Link
US (2) US7906283B2 (https=)
EP (1) EP2087136A2 (https=)
JP (1) JP2010508029A (https=)
CA (1) CA2667812A1 (https=)
WO (1) WO2008052167A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166112A1 (en) * 2008-09-18 2010-03-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (TESI)
WO2010031712A3 (en) * 2008-09-18 2010-05-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)
WO2015006645A1 (en) 2013-07-11 2015-01-15 The Johns Hopkins University A dna methylation and genotype specific biomarker of suicide attempt and/or suicide ideation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11122997B2 (en) 2015-04-17 2021-09-21 Mayo Foundation For Medical Education And Research Modulating the aryl hydrocarbon receptor system to treat major depressive disorder
CA2891830A1 (en) 2015-05-15 2016-11-15 Centre For Addiction And Mental Health Genetic markers for suicide risk and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1410036A2 (en) 2001-01-19 2004-04-21 Mindsense Biosystems Ltd. Methods and compositions for diagnosing and treating a subject having depression
US7083921B2 (en) 2001-08-29 2006-08-01 The Board Of Trustees Of The Leland Stanford Junior University Method to determine the risk for side effects of an SSRI treatment in a person
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
WO2004103394A2 (en) * 2003-05-15 2004-12-02 University Of Chicago Method and compositions for nerve regeneration
US20050069936A1 (en) 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
US20060160119A1 (en) 2005-01-14 2006-07-20 Barbara Turner Genetic screening for improving treatment of patients diagnosed with depression
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SNP [Online] 21 September 2001 (2001-09-21), "A to C change at intron 1 of GRIK2 gene" XP002487400 retrieved from NCBI Database accession no. ss3529374 *
LAJE ET AL.: "Genetic markers of suicidal emerging during antidepressant treatment" AMERICAN JOURNAL OF MEDICAL GENETICS, vol. 141B, no. 7, 5 October 2006 (2006-10-05), pages 724-725, XP008093973 *
MURPHY DENNIS L ET AL: "Serotonin transporter: gene, genetic disorders, and pharmacogenetics." MOLECULAR INTERVENTIONS APR 2004, vol. 4, no. 2, April 2004 (2004-04), pages 109-123, XP002487448 ISSN: 1534-0384 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166112A1 (en) * 2008-09-18 2010-03-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (TESI)
WO2010031712A3 (en) * 2008-09-18 2010-05-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)
WO2015006645A1 (en) 2013-07-11 2015-01-15 The Johns Hopkins University A dna methylation and genotype specific biomarker of suicide attempt and/or suicide ideation
EP3019630A4 (en) * 2013-07-11 2017-03-15 The Johns Hopkins University A dna methylation and genotype specific biomarker of suicide attempt and/or suicide ideation

Also Published As

Publication number Publication date
EP2087136A2 (en) 2009-08-12
US20080102467A1 (en) 2008-05-01
US7906283B2 (en) 2011-03-15
CA2667812A1 (en) 2008-05-02
JP2010508029A (ja) 2010-03-18
WO2008052167A3 (en) 2008-11-13
US20110118133A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
Kohen et al. Association of serotonin transporter gene polymorphisms with poststroke depression
US7795033B2 (en) Methods to predict the outcome of treatment with antidepressant medication
JP5535914B2 (ja) Ｓｎｐ遺伝子型に基づく抗精神病薬治療
JP2014530819A (ja) 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
Chen et al. Mitochondrial ND5 T12338C, tRNACys T5802C, and tRNAThr G15927A variants may have a modifying role in the phenotypic manifestation of deafness‐associated 12S rRNA A1555G mutation in three Han Chinese pedigrees
WO2013160315A2 (en) Genetic predictors of response to treatment with crhr1 antagonists
US20040248092A1 (en) Methods of screening for parkinsons's disease
WO2008086579A1 (en) Diagnostic methods and agents
US20110118133A1 (en) Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
US20110086777A1 (en) Method for autism prediction
US20110091899A1 (en) Combination of risk alleles associated with autism
WO2007095580A2 (en) Treatment response in generalized social phobia
Anitha et al. Gene and expression analyses reveal enhanced expression of pericentrin 2 (PCNT2) in bipolar disorder
EP2948563B1 (en) Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment
KR102158673B1 (ko) 양극성장애 환자의 계절성 또는 일주기 변화 진단을 위한 단일염기다형성 마커를 이용한 정보 제공 방법
US20040076953A1 (en) Detection of antidepressant induced mania
AU2005250142B2 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
US10731219B1 (en) Method for preventing progression to metabolic syndrome
CA2729821A1 (en) Genetic markers associated with degenerative disc disease and uses thereof
Torres Highly Penetrant Alterations of a Critical Region Including BDNF in Human Psychopathology and Obesity
Amstadter et al. Selected summaries from the XVII World Congress of Psychiatric Genetics, San Diego, California, USA, 4–8 November 2009
Rust The influence of childhood trauma and epigenetic variation in OXTR on anxiety proneness and structural neuroimaging measures in a South African adolescent cohort
US20110135572A1 (en) Compositions and methods for diagnosing late-onset alzheimer's disease
JP2007222134A (ja) 高血圧の遺伝的リスク検出法
Hayden et al. Genetics of bipolar disorder

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2009534893

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2667812

Country of ref document: CA

Ref document number: 2007868595

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868595

Country of ref document: EP

Kind code of ref document: A2